Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements. 2018

Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
Department of Pharmaceutical Sciences, Università degli Studi di Milano, via G. Colombo, 71, 20133 Milano, Italy. Electronic address: francesco.cilurzo@unimi.it.

Orodispersible dosage forms have a growing presence in the pharmaceutical market because their administration can improve the bioavailability of some drugs and their prescription can ameliorate patient adherence and/or compliance. Here, we review the main features of orodispersible tablets, including oral lyophilisates, and orodispersible films along with their main production technologies. We summarize the bioavailability data and critically discussed their potential to improve patient adherence and/or compliance. We revisit this information in light of both the European Union (EU) and US regulatory frameworks, focusing on the differences in the definitions of such dosage forms and the requirements for marketing authorization.

UI MeSH Term Description Entries
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D040541 Marketing Activity involved in transfer of goods from producer to consumer or in the exchange of services. Audience Research,Market Research,Research, Audience,Research, Market

Related Publications

Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
July 1967, Canadian Medical Association journal,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
September 1967, Canadian Medical Association journal,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
July 1967, Canadian Medical Association journal,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
September 1974, Pharmazie in unserer Zeit,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
January 2024, Pharmaceutics,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
January 1977, Farmatsiia,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
January 1983, Journal de pharmacie de Belgique,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
August 1973, Die Pharmazie,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
September 2022, Molecular pharmaceutics,
Francesco Cilurzo, and Umberto M Musazzi, and Silvia Franzé, and Francesca Selmin, and Paola Minghetti
January 1990, Journal of pharmaceutical and biomedical analysis,
Copied contents to your clipboard!